Group 1 - The core viewpoint of the news highlights the recent performance and financial status of Rui Li Medical Beauty, indicating a mixed performance in the stock market and financial results [1][2]. - As of August 21, the Hang Seng Index fell by 0.24%, while Rui Li Medical Beauty's stock price increased by 11.67% to HKD 0.134 per share, with a trading volume of 2.114 million shares and a turnover of HKD 280,800 [1]. - Over the past month, Rui Li Medical Beauty has seen a cumulative increase of 5.26%, and a year-to-date increase of 12.15%, which is lower than the Hang Seng Index's increase of 25.45% [1]. Group 2 - Financial data shows that for the year ending December 31, 2024, Rui Li Medical Beauty achieved total revenue of CNY 199 million, a year-on-year increase of 5.26%, while the net profit attributable to shareholders was a loss of CNY 59.212 million, a decrease of 82.43% [1]. - The gross profit margin stands at 35.82%, and the debt-to-asset ratio is 61.78% [1]. - Currently, there are no institutional investment ratings for Rui Li Medical Beauty [1]. Group 3 - Rui Li Medical Beauty is a leading provider of medical beauty services in Zhejiang Province, China, offering a wide range of services including cosmetic surgery, minimally invasive beauty services, and skin beauty services [2]. - The company also provides medical beauty management consulting services to third-party medical beauty institutions and has begun to develop a sales network for medical beauty equipment products [2]. - As of December 31, 2021, Rui Li Medical Beauty operated four private profit-making medical beauty service institutions in China, with an average industry experience of over ten years among its more than 30 practicing physicians [2].
瑞丽医美（02135.HK）8月21日收盘上涨11.67%，成交28.08万港元